OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
MATD3$5.1258

Hospital Mater Dei SA

Healthcare Facilities & ServicesVerified

Hospital Mater Dei SA has a market price of 5.12 BRL and a market cap of 1,699,314,816 BRL, with a price-to-book ratio of 1.09 and a price-to-tangible-book ratio of 1.09. The company's enterprise value to EBITDA is -5.44, indicating a negative EBITDA, and an enterprise value to revenue of 6.07. The company's return on equity is -0.2991, and return on assets is -0.0942, both significantly below industry norms. The company's profitability is underperforming relative to industry standards, with a negative operating income of -652,319,000 BRL and a net income of -464,267,000 BRL. The debt-to-equity ratio is 1.36, and the current ratio is 2.49, suggesting moderate liquidity but a high level of leverage. The company's free cash flow is -485,723,000 BRL, indicating a significant outflow of cash. Hospital Mater Dei SA's revenue is concentrated in a single segment, with no disclosed geographic diversification. The company's capital expenditure of -131,064,000 BRL reflects ongoing investment in infrastructure and facilities. The company's operating cash flow of 45,656,000 BRL is positive but insufficient to cover the free cash flow outflow. The company's growth trajectory is uncertain, with a negative operating income and net income. The company's revenue of 585,343,000 BRL is a key metric to monitor for future performance. Analysts have provided a mean price target of 6.76 BRL and a median price target of 7.00 BRL, with a mean recommendation of 2.50, indicating a mixed outlook. The company faces moderate liquidity risk, with a negative net cash position after subtracting total debt. The risk of dilution is low, and the company has not issued additional shares recently. The company's financial structure and performance suggest a need for careful monitoring of liquidity and profitability. Recent events and filings indicate that the company is under pressure to improve its financial performance. The company's operating cash flow is positive, but the free cash flow is negative, indicating a need for cost management and revenue growth. The company's capital expenditure is a significant outflow, and the company's debt levels are high.

30-day price · MATD3-0.76 (-12.9%)
Low$5.00High$5.97Close$5.12As of27 May, 00:00 UTC
Profile
CompanyHospital Mater Dei SA
TickerMATD3.SA
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Hospital Mater Dei SA operates in the healthcare sector, providing medical services and facilities, and generates revenue primarily through patient care and related healthcare services.

Classification. Hospital Mater Dei SA is classified under the Healthcare Facilities & Services industry within the Healthcare Services & Equipment business sector, with a classification confidence of 0.92.

Hospital Mater Dei SA has a market price of 5.12 BRL and a market cap of 1,699,314,816 BRL, with a price-to-book ratio of 1.09 and a price-to-tangible-book ratio of 1.09. The company's enterprise value to EBITDA is -5.44, indicating a negative EBITDA, and an enterprise value to revenue of 6.07. The company's return on equity is -0.2991, and return on assets is -0.0942, both significantly below industry norms. The company's profitability is underperforming relative to industry standards, with a negative operating income of -652,319,000 BRL and a net income of -464,267,000 BRL. The debt-to-equity ratio is 1.36, and the current ratio is 2.49, suggesting moderate liquidity but a high level of leverage. The company's free cash flow is -485,723,000 BRL, indicating a significant outflow of cash. Hospital Mater Dei SA's revenue is concentrated in a single segment, with no disclosed geographic diversification. The company's capital expenditure of -131,064,000 BRL reflects ongoing investment in infrastructure and facilities. The company's operating cash flow of 45,656,000 BRL is positive but insufficient to cover the free cash flow outflow. The company's growth trajectory is uncertain, with a negative operating income and net income. The company's revenue of 585,343,000 BRL is a key metric to monitor for future performance. Analysts have provided a mean price target of 6.76 BRL and a median price target of 7.00 BRL, with a mean recommendation of 2.50, indicating a mixed outlook. The company faces moderate liquidity risk, with a negative net cash position after subtracting total debt. The risk of dilution is low, and the company has not issued additional shares recently. The company's financial structure and performance suggest a need for careful monitoring of liquidity and profitability. Recent events and filings indicate that the company is under pressure to improve its financial performance. The company's operating cash flow is positive, but the free cash flow is negative, indicating a need for cost management and revenue growth. The company's capital expenditure is a significant outflow, and the company's debt levels are high.
Key takeaways
  • Hospital Mater Dei SA is operating at a loss, with a negative operating income and net income.
  • The company's liquidity is moderate, with a current ratio of 2.49 but a negative net cash position.
  • The company's debt-to-equity ratio is 1.36, indicating a high level of leverage.
  • Analysts have a mixed outlook, with a mean price target of 6.76 BRL and a median price target of 7.00 BRL.
  • The company's free cash flow is negative, indicating a need for cost management and revenue growth.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyBRL
Revenue$585.3M
Gross profit$174.9M
Operating income-$652.3M
Net income-$464.3M
R&D
SG&A
D&A
SBC
Operating cash flow$45.7M
CapEx-$131.1M
Free cash flow-$485.7M
Total assets$4.93B
Total liabilities$3.38B
Total equity$1.55B
Cash & equivalents$257.4M
Long-term debt$2.11B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$1.02B$242.3M$144.9M$37.0M
FY-3$1.76B$337.9M$103.5M-$62.2M
FY0$2.18B$353.7M$110.5M$86.8M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY0
PeriodAssetsEquityCashDebt
FY-4$4.09B$1.64B$984.7M
FY-3$4.93B$1.62B$231.0M
FY0$4.31B$1.46B$595.3M
PeriodOCFCapExFCFSBC
FY-4$153.2M-$123.9M$37.0M
FY-3-$61.7M-$215.9M-$62.2M
FY0$224.3M-$60.9M$86.8M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$585.3M-$652.3M-$464.3M-$485.7M
FQ-4$499.3M$69.3M$19.9M$34.5M
FQ-3$545.8M$88.0M$26.2M$47.5M
FQ-2$567.9M$98.1M$26.9M$34.5M
FQ-1$562.3M$98.3M$37.5M-$4.3M
FQ0$575.0M$95.5M$33.2M$49.9M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$4.93B$1.55B$257.4M
FQ-4$4.38B$1.45B$613.5M
FQ-3$4.34B$1.45B$606.6M
FQ-2$4.40B$1.46B$650.4M
FQ-1$4.31B$1.46B$595.3M
FQ0$4.33B$1.50B$553.8M
PeriodOCFCapExFCFSBC
FQ-7$45.7M-$131.1M-$485.7M
FQ-4$51.8M-$13.0M$34.5M
FQ-3$61.1M-$19.8M$47.5M
FQ-2$137.7M-$40.6M$34.5M
FQ-1$224.3M-$60.9M-$4.3M
FQ0$563.0k-$11.6M$49.9M
Valuation
Market price$5.12
Market cap$1.70B
Enterprise value$3.55B
P/E
Reported non-GAAP P/E
EV/Revenue6.1
EV/Op income
EV/OCF77.8
P/B1.1
P/Tangible book1.1
Tangible book$1.55B
Net cash-$1.85B
Current ratio2.5
Debt/Equity1.4
ROA-9.4%
ROE-29.9%
Cash conversion-10.0%
CapEx/Revenue-22.4%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricMATD3Activity
Op margin-111.4%7.7% medp25 -2.4% · p75 15.5%bottom quartile
Net margin-79.3%5.9% medp25 -3.8% · p75 12.8%bottom quartile
Gross margin29.9%45.5% medp25 31.1% · p75 62.9%bottom quartile
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-22.4%-7.0% medp25 -14.9% · p75 -3.2%bottom quartile
Debt / equity136.0%25.0% medp25 3.8% · p75 63.3%top quartile
Observations
IR observations
Mean price target6.76 BRL
Median price target7.00 BRL
High price target7.00 BRL
Low price target6.30 BRL
Mean recommendation2.50 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count3.00
Hold count3.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate0.52 BRL
Last actual EPS0.33 BRL
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-09 10:34 UTC#57e7190b
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 12:27 UTCJob: b8087c59